Anixa Biosciences to Present at Water Tower Research Insights Conference

Biotech company to discuss breast cancer vaccine and ovarian cancer CAR-T therapy progress.

Apr. 7, 2026 at 2:28pm

Got story updates? Submit your updates here. ›

A translucent, ghostly X-ray image revealing the intricate internal structures of a medical device or cancer cell, conceptually representing the advanced cancer treatments being developed by Anixa Biosciences.Anixa Biosciences' innovative cancer therapies, including a breast cancer vaccine and an ovarian cancer CAR-T therapy, offer new hope for patients.San Jose Today

Anixa Biosciences, a biotechnology company focused on cancer treatment and prevention, announced that CEO Dr. Amit Kumar will participate in the upcoming Water Tower Research Insights Conference on April 14, 2026. The presentation will cover Anixa's breast cancer vaccine, which met primary endpoints and generated immune responses in 74% of participants in a Phase 1 trial, as well as its ovarian cancer CAR-T therapy lira-cel, which is exhibiting positive survival data in an ongoing Phase 1 study.

Why it matters

Anixa's vaccine and CAR-T pipeline represent promising advancements in cancer research, particularly for hard-to-treat cancers like breast and ovarian. The company's partnerships with leading institutions like Moffitt Cancer Center and Cleveland Clinic provide access to cutting-edge technologies and expertise. As Anixa continues to progress these therapies, the insights shared at the conference will be of interest to investors tracking innovation in the oncology space.

The details

Anixa's breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% of participants in a Phase 1 clinical trial. The company's ovarian cancer CAR-T therapy, lira-cel, is also exhibiting positive survival data in an ongoing Phase 1 trial. Dr. Amit Kumar, Anixa's Chairman and CEO, will present an overview of the company and these pipeline updates at the Water Tower Research Insights Conference.

  • The Water Tower Research Insights Conference will take place on April 14, 2026.
  • Anixa's breast cancer vaccine completed a Phase 1 clinical trial.
  • Anixa's ovarian cancer CAR-T therapy, lira-cel, is in an ongoing Phase 1 clinical trial.

The players

Anixa Biosciences, Inc.

A clinical-stage biotechnology company focused on the treatment and prevention of cancer, with a therapeutic portfolio that includes a breast cancer vaccine and an ovarian cancer CAR-T therapy.

Dr. Amit Kumar

The Chairman and CEO of Anixa Biosciences, who will present at the Water Tower Research Insights Conference.

Moffitt Cancer Center

A world leader in cancer immunotherapy treatments, collaborating with Anixa on the development of the ovarian cancer CAR-T therapy lira-cel.

Cleveland Clinic

A research institution that developed the breast and ovarian cancer vaccines exclusively licensed to Anixa.

Robert Sassoon

The Managing Director at Water Tower Research, who will host the presentation by Dr. Amit Kumar.

Got photos? Submit your photos here. ›

What’s next

Anixa Biosciences will present at the Water Tower Research Insights Conference on April 14, 2026, where the company will provide updates on its breast cancer vaccine and ovarian cancer CAR-T therapy.

The takeaway

Anixa's partnerships with leading cancer research institutions like Moffitt Cancer Center and Cleveland Clinic have enabled the development of promising new therapies for hard-to-treat cancers. As the company continues to advance these innovative treatments, the insights shared at the upcoming conference will be valuable for investors tracking progress in the oncology space.